JAAD Case Rep 2021 Dec 20;18:26-28. Epub 2021 Oct 20.
Department of Dermatology, University of Texas Health Science Center at Houston, Houston, Texas.
Sci Rep 2021 Nov 19;11(1):22574. Epub 2021 Nov 19.
Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Diseases of the Musculoskeletal System, IDIVAL, Avenida Cardenal Herrera Oria s/n, Lab. 201/202, 39011, Santander, Spain.
Mucin 1/Krebs von den Lungen-6 (KL-6) is proposed as a serum biomarker of several interstitial lung diseases (ILDs), including connective tissue disorders associated with ILD. However, it has not been studied in a large cohort of Caucasian antisynthetase syndrome (ASSD) patients. Consequently, we assessed the role of MUC1 rs4072037 and serum KL-6 levels as a potential biomarker of ASSD susceptibility and for the differential diagnosis between patients with ILD associated with ASSD (ASSD-ILD +) and idiopathic pulmonary fibrosis (IPF). Read More
Expert Opin Investig Drugs 2021 Nov 14. Epub 2021 Nov 14.
Muscle Immunobiology Group, Department of Neurology, Neuromuscular Center, University Medical Center Göttingen, Göttingen, Germany.
Introduction: Due to new insights into the pathogenesis of inflammatory myopathies -in short myositis- and the urgent need for new treatment options in patients who are refractory to standard therapy, multiple novel drugs have been developed and studied in clinical trials. In light of this exciting development, a critical evaluation of the present data is necessary in order to identify the best pathway to future treatment of inflammatory myopathies.Areas Covered: This review focuses on the current evidence from clinical trials in myositis and encompasses dermatomyositis, polymyositis, necrotizing myopathy, antisynthetase-syndrome, overlap myositis and inclusion body myositis. Read More
Crit Rev Clin Lab Sci 2021 Nov 12:1-22. Epub 2021 Nov 12.
Department of Neurology, University Hospital of Ioannina, Ioannina, Greece.
Idiopathic inflammatory myopathies (IIMs) are rare autoimmune disorders affecting primarily muscles, but other organs can be involved. This review describes the clinical features, diagnosis and treatment for IIMs, namely polymyositis (PM), dermatomyositis (DM), sporadic inclusion body myositis (sIBM), immune-mediated necrotizing myopathy (IMNM), and myositis associated with antisynthetase syndrome (ASS). The diagnostic approach has been updated recently based on the discovery of circulating autoantibodies, which has enhanced the management of patients. Read More
Rheumatol Adv Pract 2021 Nov 5;5(Suppl 2):ii10-ii18. Epub 2021 Nov 5.
Department of Clinical Immunology and Rheumatology.
Objectives: The aim was to describe the clinical profile and outcomes in patients with antisynthetase syndrome (ASS) from a tertiary care centre.Methods: The clinical data and investigations of all patients classified as ASS by Connors criteria over 5 years were recorded, and they were followed up prospectively. The median (interquartile range) was used for descriptive statistics. Read More